Skip to main content

Fiscal Wizard · Single-issue tearsheet

COLL / Jun 21, 2026 Run #7529

COLL

Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Composite verdict

D 33.5 / 100
Bearish setup · Reversal 12 drivers · 6 gates blocking
  • Vortex Signal
  • Elder Force Index
  • Parabolic SAR Flip
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 28th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 10Mean-reversion Neutral 43

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -33%
Asset value $9.30Earnings power value $48.55Price $33.54

The discount is mostly unpriced earnings power: price ($33.54) sits between asset value ($9.30) and no-growth earnings power value ($48.55).

Fundamentals Above average

66.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
OCF to Net Income 0
Revenue Growth (YoY) 100
Cash Conversion 0
Free Cash Flow Yield 100
Inventory Turnover 0

Technicals Bearish

0.1 / 100

Bearish setup leads (Vortex Signal, Elder Force Index, Parabolic SAR Flip); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Vortex Signal 9
Elder Force Index 9
Parabolic SAR Flip 11

Risk Gates

6 blocking 3 caution

6 guards active, 20 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for COLL.